Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE SODIUM 20 versus HYPAQUE 76.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE SODIUM 20 versus HYPAQUE 76.
HYPAQUE SODIUM 20% vs HYPAQUE-76
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Hypaque sodium is an ionic monomeric iodinated contrast medium that absorbs X-rays due to its iodine content, providing radiographic contrast. It increases the density of vascular structures and organ parenchyma, allowing visualization during imaging procedures.
HYPAQUE-76 (diatrizoate meglumine and diatrizoate sodium) is an ionic iodinated contrast agent that attenuates X-rays, providing radiographic contrast. Its mechanism involves high iodine content (76%) that absorbs X-rays, distinguishing anatomical structures in imaging procedures.
Intravascular contrast agent for computed tomography (CT) imagingIntravascular contrast agent for angiographyIntravascular contrast agent for urographyIntravascular contrast agent for digital subtraction angiographyOral contrast agent for gastrointestinal studies (off-label)
Intravascular angiography (including cerebral, coronary, peripheral)Contrast enhancement for computed tomography (CT)Intravenous urographyVentriculographyMyelography (although less common due to neurotoxicity)
Intravenous: 30-60 mL (6-12 g iodine) administered as a bolus or infusion for excretory urography; may be repeated up to a total of 125 mL (25 g iodine). Intra-arterial: Variable based on procedure, typically 8-30 mL for selective angiography.
Intravenous: 50-100 mL (as a 76% solution, 370 mg iodine/mL) for contrast imaging, administered as a bolus or infusion; maximum 300 mL per procedure.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours in normal renal function; prolonged in renal impairment.
Terminal elimination half-life of 1.5-2 hours in normal renal function. Prolonged to >10 hours in moderate renal impairment (CrCl 30-50 mL/min). Closely correlates with creatinine clearance.
Hypaque sodium is not significantly metabolized and is excreted unchanged primarily by glomerular filtration.
Not metabolized; excreted unchanged primarily via glomerular filtration in the kidneys.
Renal: >95% unchanged via glomerular filtration within 24 hours; <5% biliary/fecal.
Primarily renal; >95% excreted unchanged in urine within 24 hours via glomerular filtration. Fecal excretion minimal (<5%). Biliary excretion negligible.
Minimal, <10%; primarily albumin.
<5% bound to plasma proteins (primarily albumin). Minimal binding due to high water solubility.
0.2-0.3 L/kg; limited to extracellular fluid.
Vd of 0.2-0.3 L/kg, approximates extracellular fluid volume. Does not enter cells or cross blood-brain barrier under normal conditions.
Oral: <1% (poor absorption, used for GI opacification); not applicable for IV.
Intravenous: 100%. Intra-arterial: 100%. No oral bioavailability due to lack of absorption (not administered orally).
GFR < 30 mL/min: Avoid use; if necessary, reduce dose by 50% and ensure adequate hydration. GFR 30-60 mL/min: Use with caution, consider lower doses and monitor renal function. GFR > 60 mL/min: No adjustment required.
eGFR <30 mL/min/1.73 m²: avoid use unless essential; consider alternative agent. eGFR 30-59 mL/min/1.73 m²: ensure adequate hydration, monitor renal function. No specific dose reduction recommended; use minimal volume.
No specific adjustment for mild to moderate impairment (Child-Pugh A or B). Severe impairment (Child-Pugh C): Use with caution due to potential for delayed excretion; monitor for adverse effects.
Child-Pugh Class A/B: no adjustment required. Class C: use with caution due to increased risk of contrast-induced nephropathy; monitor renal function.
Intravenous: 1-2 mL/kg (0.2-0.4 g iodine/kg) for excretory urography, not to exceed 30 mL. Intra-arterial: 0.5-1 mL/kg per injection, adjusted based on procedure.
Intravenous: 1-2 mL/kg (up to 100 mL) of 76% solution; maximum 3 mL/kg. Adjust based on indication and imaging modality.
Start with lower doses (e.g., 50% of adult dose) and titrate upward as needed. Monitor renal function closely due to age-related decline; ensure adequate hydration.
Use lowest effective volume; ensure adequate hydration; monitor renal function due to age-related decline in glomerular filtration rate.
Not for intrathecal use. Intrathecal administration may cause severe adverse reactions including convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, and death.
Not recommended for intrathecal use due to risk of severe neurological adverse reactions including seizure, coma, and death.
["Risk of acute kidney injury, particularly in patients with pre-existing renal impairment, diabetes mellitus, or volume depletion","Anaphylactoid reactions, including anaphylaxis, bronchospasm, and hypotension","Thyroid storm in patients with hyperthyroidism or thyroid nodules","Severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson syndrome","Cardiovascular adverse events including arrhythmias and cardiac arrest","Vasovagal reactions","Extravasation leading to tissue injury"]
["Risk of anaphylactic or anaphylactoid reactions; premedication may be considered in high-risk patients.","Contrast-induced nephropathy (CIN) risk, especially in patients with pre-existing renal impairment, diabetes, or dehydration.","Thyroid storm in patients with hyperthyroidism or autonomously functioning thyroid tissue.","Extravasation risk leading to tissue necrosis.","Acute severe adverse reactions including cardiovascular collapse, bronchospasm, and seizures."]
["Known hypersensitivity to Hypaque sodium or any of its components","History of anaphylactoid reaction to iodinated contrast media","Intrathecal administration (contraindicated due to risk of neurotoxicity)","Severe renal impairment (e.g., estimated glomerular filtration rate <30 mL/min/1.73 m²)","Concurrent administration of metformin in patients with acute kidney injury or severe renal impairment (risk of lactic acidosis)"]
["Absolute: Known hypersensitivity to diatrizoate or any component; intrathecal administration.","Relative: Renal impairment (eGFR <30 mL/min/1.73m²), unstable congestive heart failure, multiple myeloma, pheochromocytoma, sickle cell disease, active hyperthyroidism."]
Data Pending Review
Data Pending Review
No specific food interactions. Avoid alcohol for 24 hours before procedure to reduce risk of nausea and vomiting. Maintain adequate hydration with clear fluids.
No specific food interactions. Maintain adequate hydration with water before and after the procedure unless contraindicated (e.g., heart failure).
Hypaque Sodium 20% (diatrizoate sodium) is a radiocontrast agent. It is not known to be teratogenic in humans. However, because it contains iodine, fetal thyroid function may be affected, particularly if exposure occurs during the second or third trimester. The risk of fetal hypothyroidism is theoretical and low with single exposure. Use only if clearly needed.
HYPAQUE-76 (diatrizoate meglumine) is an iodinated contrast agent. In animal studies, no teratogenic effects were observed at clinically relevant doses. However, iodine-containing contrast agents can cross the placenta and may have potential to affect fetal thyroid function, particularly during the second and third trimester when fetal thyroid is active. Transient neonatal hypothyroidism has been reported after in utero exposure. The risk is considered low with single diagnostic exposure, but caution is warranted.
Minimal excretion into breast milk; M/P ratio is not available. The amount ingested by a nursing infant is likely negligible. However, due to potential hypersensitivity or iodine effects, caution is advised. The manufacturer recommends discontinuing breastfeeding for 24 hours after administration, but this may be excessive. Discuss with patient.
Diatrizoate is excreted into breast milk in very small amounts (<1% of maternal dose). The M/P ratio is unknown. The theoretical risk of direct toxicity or allergic reaction to the infant is negligible. The American College of Radiology recommends that breastfeeding can be continued without interruption after contrast administration, although some sources suggest discarding milk for 12-24 hours post-exposure out of caution.
No specific dose adjustments are recommended for pregnancy. However, consider the increased plasma volume and renal blood flow in pregnancy; the contrast agent is renally excreted, so clearance may be slightly increased, but no dose change is typically needed. Use the lowest necessary dose.
Pregnancy does not significantly alter the pharmacokinetics of diatrizoate as it is a low-molecular-weight, water-soluble agent that distributes in extracellular fluid. No dose adjustment is required due to pregnancy. However, to minimize fetal exposure, the lowest effective dose should be used.
Category C
Category C
Administer slowly intravenously to minimize pain and thrombosis risk. Pre-warm to body temperature to reduce viscosity. Ensure adequate hydration before and after use to prevent renal impairment. Have emergency equipment available for anaphylactoid reactions. Use with caution in patients with sickle cell disease due to risk of sickling. Contraindicated in myelography due to neurotoxicity. Check for iodine allergy history.
Hypaque-76 (diatrizoate meglumine and diatrizoate sodium) is a high-osmolar ionic contrast agent used for CT, angiography, and urography. Pre-hydrate patients to reduce nephrotoxicity. Use with caution in patients with multiple myeloma, pheochromocytoma, or sickle cell disease due to risk of adverse reactions. Have emergency equipment and drugs (e.g., epinephrine, antihistamines) available. Consider premedication with corticosteroids and antihistamines in high-risk patients (e.g., previous contrast reaction, asthma).
You may experience a warm sensation or metallic taste during injection.Drink plenty of fluids before and after the procedure to protect your kidneys.Report any symptoms of allergic reaction such as hives, itching, or difficulty breathing immediately.You may have to fast for a few hours before the test depending on the procedure.Inform your doctor if you are pregnant, diabetic, or have kidney problems.You may notice a salty or metallic taste after the injection.
Inform your doctor if you have any allergies, especially to contrast agents or iodine.Tell your doctor about all medications you take, especially metformin (may need to stop temporarily).You may experience warmth, flushing, or a metallic taste during injection.Drink plenty of fluids before and after the procedure unless instructed otherwise.Report any difficulty breathing, hives, or swelling immediately to the healthcare team.